Randox Laboratories has launched an automated laboratory assay for heart-type fatty acid binding protein to improve the diagnosis and management of patients with suspected acute coronary syndrome.
The company said the rapid, fully quantitative assay means that heart-type fatty acid binding protein (H-FABP) can now be used routinely in the acute clinical setting.
Recent trials have shown that H-FABP provides significant diagnostic value, particularly during the early hours following acute coronary syndrome (ACS) symptom onset.
The use of H-FABP, alongside Troponin, offers the potential to rule out ACS in many patients from the time of presentation.
These results have also been shown to apply with the new generation of high-sensitivity Troponins (hsTn).
